Sai Life Sciences Ltd reports Q2 FY27 consolidated revenue of ₹658.6 crore and net profit of ₹98.3 crore
- Revenue rose 22.5% year on year and 18.8% sequentially; net profit increased 17.3% year on year and 34.2% sequentially.
- Calculated consolidated EBITDA margin was approximately 28.3%; no exceptional items were reported.
- Board approved unaudited Q2 and half-year results ended 30 September 2026; limited-review conclusion was unmodified.
- Appointed three senior management personnel and approved allotment of 1,08,005 shares on exercise of employee stock options.
